A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy

Inclusion Criteria:

* Age ≥18 years at the time of informed consent.
* Histologically confirmed gastric or gastroesophageal junction (GEJ)adenocarcinoma.
* HER2-negative disease, as determined by standard testing methods.
* Prior D2 radical gastrectomy with R0 resection.
* Disease recurrence during adjuvant chemotherapy or within 6 months after completion of adjuvant chemotherapy.
* At least one measurable lesion according to RECIST version 1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
* Adequate organ and bone marrow function.
* Life expectancy of at least 3 months.
* Ability to understand and willingness to sign written informed consent.

Exclusion Criteria:

* Active malignancy within the past 5 years, except for adequately treated in situ carcinoma or other cancers with a negligible risk of recurrence.
* Prior participation in another investigational drug study within 4 weeks prior to enrollment.
* Symptomatic central nervous system (CNS) metastases.
* Active autoimmune disease requiring systemic treatment.
* Uncontrolled cardiovascular disease or uncontrolled hypertension.
* History of thromboembolic events or clinically significant bleeding disorders within 6 months prior to enrollment.
* Active tuberculosis or interstitial lung disease.
* Known hypersensitivity to monoclonal antibodies or any excipients of the study drug.